Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase NA 1Phase EARLY_PHASE1 1Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 10Glioma 9Glioblastoma 8Sarcoma 7Pancreatic Neoplasms 6Neoplasms 6Neoplasm Metastasis 6Brain Neoplasms 6Neuroendocrine Tumors 4Neuroblastoma 4Lung Neoplasms 4Head and Neck Neoplasms 4Colonic Neoplasms 4Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Multiple Myeloma 3Melanoma 3Lymphoma 3Fallopian Tube Neoplasms 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Smoldering Multiple Myeloma 2Smoking Cessation 2Smoking 2Skin Neoplasms 2Sarcoma, Alveolar Soft Part 2

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Active not recruiting × Pathologic Complete Response × Clear all
NCT03832569 2026-03-05

Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors

Memorial Sloan Kettering Cancer Center

Phase EARLY_PHASE1 Active not recruiting
17 enrolled

Pathologic Complete Response

Data powered by HemOnc (CC BY 4.0) Colophon âš¡